Efineptakin alfa
- Generic Name
- Efineptakin alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2026634-47-7
- Unique Ingredient Identifier
- 3K3WC6MT6P
- Background
Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. This drug is currently being investigated in the areas of oncology, immun...
- Associated Conditions
- -
- Associated Therapies
- -
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma
DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.
NT-I7 Enhances CAR T-Cell Efficacy in DLBCL
NT-I7 enhanced CAR T factors efficacy in relapsed/refractory DLBCL patients, with an 81.1% ORR, 63.6% CR, and 18.2% PR in a phase 1b study. NT-I7, a long-acting IL-7 agent, showed safety and enhanced CAR T expansion without cytokine release syndrome or neurotoxicity.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath